Alzamend Neuro announced that it has received a notification letter from the Listing Qualifications Staff of Nasdaq, informing Alzamend that it has regained compliance with Nasdaq Listing Rule 5550. In order to regain compliance with the minimum bid price requirement, Alzamend’s common stock was required to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive trading days. The minimum bid price requirement was met on November 13. Accordingly, in the compliance notice, Nasdaq stated that the matter is now closed.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALZN:
- Alzamend Neuro submits AL001-PTSD01 IND application to FDA
- Alzamend Neuro annouces one-for-fifteen reverse stock split
- Alzamend Neuro submits AL001-MDD01 IN application to FDA
- Alzamend Neuro receives Study May Proceed letter from FDA for AL001-BD01
- Alzamend Neuro granted extension by Nasdaq panel to regain compliance
